July 20, 2026: North Carolina woman shares experience with hospitalization after telehealth prescribed weight loss drugs
Major Stories
A North Carolina woman was hospitalized after being given a dramatic increase in her dosing for compounded weight loss drugs. A North Carolina wellness spa owner was charged with crimes related to unapproved weight loss drugs.
A 54-year-old North Carolina woman was hospitalized for three days after overdosing on a compounded weight loss medication she received through a telehealth provider. Today reports that she was given a dramatic increase in her prescribed dose, a change she questioned, but was told to follow the doctor's instructions. Despite injecting a smaller amount than directed, she began violently vomiting within hours. It took her a month to recover enough to eat solid food again, and she now faces a $9,000 hospital bill.
Her story comes as North Carolina authorities allege that the owner of a wellness clinic practiced medicine without a license, charging patients thousands of dollars while forging prescription records and administering injectable substances marketed as tirzepatide at doses that exceeded the FDA-approved maximum. The case underscores concerns about the risks of receiving GLP-1 treatments from unlicensed providers and poorly regulated sources. The Tech Times, which reported on this story, cites PSM’s May 2026 update about safety risks in the GLP-1 market.
Axios is hosting, “Examining Risk and Regulation in the GLP-1 Landscape,” a live event in Washington, D.C., on July 22, 2026 to examine the rapidly evolving landscape of weight loss medications, with a particular focus on the safety, oversight, and regulation of compounded versions.
The discussion will bring together lawmakers, medical experts, and industry leaders, including Partnership for Safe Medicines Executive Director Shabbir Imber Safdar, to explore the benefits of GLP-1 therapies, the risks associated with non-FDA-approved compounded products, and what the future of these treatments could mean for patients and policymakers.
Learn about some of the dangers of unapproved peptides here.
Conversations about peptides are everywhere. PSM created a consumer explainer for those who want to learn more about growing risks associated with untested peptides as the FDA considers whether to expand compounding access to several substances. Our blog outlines five major concerns about these chemicals and argues that peptide use is becoming a large-scale public experiment fueled by online marketing and inadequate oversight, leaving consumers vulnerable to products that may be unsafe or ineffective.
Domestic
A new scholarly article argues for stronger oversight to curb fake online pharmacies. A federal judge in New Jersey sentenced members of a counterfeit oxycodone ring.
A research article in the Journal of Illicit Trade, Financial Crime, and Compliance warns that illicit online pharmacies continue to pose a major public health threat, with 95% operating outside the law and selling medicines that may be counterfeit, ineffective, or contaminated. Researchers found that these websites increasingly rely on cryptocurrency for payments and have expanded their offerings to include counterfeit cancer drugs, weight-loss medications, and other high-demand treatments. The authors argue that stronger oversight of both online pharmacies and the financial systems that support them is needed to curb the growing illicit market.
Two more members of a New Jersey drug trafficking organization were sentenced for their roles in importing massive amounts of illicit drugs, including fentanyl analogues, from China and distributing them as counterfeit prescription pills. Investigators say the group pressed the imported powders into fake pills and sold them throughout northern New Jersey. With these latest sentences, five members of the nine-person conspiracy have now received a combined 685 months in federal prison, while four others are awaiting sentencing.
Pill presses
Three bipartisan bills aimed at disrupting counterfeit pill production and fentanyl trafficking have advanced to the full committee after voice votes in their subcommittees in Congress. The Fight Illicit Pill Presses Act (H.R. 5880) would establish a regulatory framework to track pill presses and their key components. The PRESS Act (H.R. 7184) would create criminal penalties for manufacturing, distributing, or importing pill press equipment intended for illicit controlled substance production. The Stop Pills That Kill Act (H.R. 8005) would strengthen criminal penalties for illicit fentanyl and counterfeit pill manufacturing and require the DEA to develop a national strategy to combat counterfeit pills and other synthetic drugs.
PSM in the News
FDA Matters blogger Stephen Grossman suggested PSM’s recent blog, The five risks of taking untested peptides, as a resource for those seeking information about peptide compounding.
Regulators
The FDA issued a warning letter to a California-based sterile drug manufacturer, citing gross bacterial growth and insect larvae in the aseptic filling area. The company deviated from its own procedures, releasing a batch of epinephrine injections made in a contaminated environment after concluding that contamination risk was low. The FDA later recommended a recall of the product, which was undertaken in April 2026. The FDA also cited the company for repeated failures to investigate contamination events and more than 90 customer complaints, inadequate aseptic processing practices, poorly designed equipment and water systems, and significant deficiencies in its quality oversight program that could compromise the sterility of its injectable drugs.
FDA cited a California manufacturer of OTC skincare and SPF products for repeated failures to comply with current good manufacturing practices. The company repeatedly received out-of-limit microbial and chemical test results for its manufacturing water but failed to conduct adequate investigations, identify contamination sources, or properly remediate its water system, which had design flaws that could allow bacterial growth. FDA also found the company did not perform required identity testing on incoming ingredients, including components at risk for methanol and diethylene glycol and ethylene glycol contamination.
FDA also cited a New York dietary supplement manufacturer after investigators found poor sanitation and hygiene practices, including employees handling ready-to-eat powders without proper protective measures, working while ill, wearing jewelry and street clothing, and using equipment and facilities with visible contamination, residue, and unsafe storage conditions. FDA also found inadequate quality controls, including failures to establish proper product specifications, maintain complete manufacturing records, validate testing procedures, and properly investigate customer complaints. Additionally, the company’s products were considered misbranded because at least one supplement contained a major food allergen that was not properly disclosed on the label.
International
Indian authorities closed a counterfeit factory. Ukraine introduced drug tracking systems. The United Kingdom renewed warnings about botulism.
Authorities in India shut down a counterfeit drug manufacturing facility after a sting operation uncovered an international network producing fake Pregabalin-150 tablets. A raid resulted in the seizure of 300,000 counterfeit tablets and packaging materials, the sealing of the facility, and the arrest of its owner as authorities continue investigating the broader supply chain.
The UK’s Medicines and Healthcare products Regulatory Agency strengthened safety warnings for botulinum toxin type A products after reports of rare cases of botulism linked to their use. Updated patient information now highlights symptoms of toxin spread, including difficulty swallowing, breathing problems, slurred speech, and muscle weakness, which can occur days to weeks after treatment. The agency also warned that unlicensed and counterfeit botulinum toxin products are especially dangerous and urged patients to seek treatment only from qualified practitioners using authorized products.
Incidences of botulism from these injectables have also occurred in the U.S. Learn more:
Ukraine registered the National Organization for the Verification of Medicinal Products, a key step toward creating a national medicine verification system designed to combat counterfeit drugs. The system will use 2D coding technology to verify the authenticity of medicine packaging, improve supply chain transparency, and align Ukraine’s pharmaceutical standards with European approaches.